A Trial of RAD001/Capecitabine in Refractory Gastric Cancer

Status Completed

Clinical Trial Summary

Capecitabine is an oral fluoropyrimidine that has been shown to be effective in the treatment of metastatic gastric and colorectal cancer patients. On the basis of capecitabine-based chemotherapy which is accepted as a standard regimen in gastric cancer, we will perform the phase I/II study with all-oral regimen of RAD001 with capecitabine for these refractory gastric cancer patients.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01099527
Study type	Interventional
Source	Samsung Medical Center
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	October 2009
Completion date	December 2013

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04618809` - Improving the Approach to and Management of the Older Patient With Metastatic Gastric Cancer	N/A
Recruiting	`NCT02668380` - An Open Label, Prospective, Multicentre, Non-interventional Study of Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer	N/A
Completed	`NCT03121807` - Home Parenteral Nutrition for Malnourished Unresectable Stage IV Gastric Cancer	N/A
Recruiting	`NCT04358354` - Triplet Combination of Cytotoxics as First-line Treatment for Metastatic Gastric Cancer	Phase 3
Completed	`NCT00253370` - Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer	Phase 2
Recruiting	`NCT02002195` - Modified Folinic Acid-Fluorouracil-Oxaliplatin Regimen + Capecitabine for Elderly With Metastatic Gastric Cancer
Recruiting	`NCT06008925` - Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer	Phase 1/Phase 2
Recruiting	`NCT05714124` - Liver Embolization Approaches for Tumor Management
Recruiting	`NCT02855788` - Metronomic Chemotherapy in Advanced Gastric Cancer	Phase 2
Recruiting	`NCT03154983` - The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer	Phase 2
Not yet recruiting	`NCT04263870` - Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction	Phase 2
Active, not recruiting	`NCT01359397` - Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer	Phase 2
Recruiting	`NCT04739202` - Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)	Phase 2
Completed	`NCT03409848` - Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma	Phase 2
Recruiting	`NCT05859477` - Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer	Phase 2
Recruiting	`NCT05955833` - 89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study	Phase 1
Terminated	`NCT01528501` - Histone Deacetylases - Gastric Cancer (HDAC-GaCa-2008)	Phase 2
Completed	`NCT03751761` - GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study	Phase 1/Phase 2
Recruiting	`NCT05024812` - Fruquintinib Combined With Toripalimab and SOX Regimen in the First-line Treatment of Advanced Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma	Phase 1/Phase 2
Active, not recruiting	`NCT03614013` - Resistance to Immunotherapy in Gastric Cancer